Abvc Biopharma Stock Today

ABVC Stock  USD 1.08  0.01  0.93%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 82

 
High
 
Low
Very High
ABVC Biopharma is trading at 1.08 as of the 23rd of May 2024, a 0.93% increase since the beginning of the trading day. The stock's open price was 1.07. ABVC Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for ABVC Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of April 2024 and ending today, the 23rd of May 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of October 2017
Category
Healthcare
Classification
Health Care
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 10.56 M outstanding shares of which 637.62 K shares are presently shorted by private and institutional investors with about 0.41 trading days to cover. More on ABVC Biopharma

ABVC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ABVC Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ABVC Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering ABVC Biopharma report their recommendations after researching ABVC Biopharma's financial statements, talking to executives and customers, or listening in on ABVC Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ABVC Biopharma. The ABVC consensus assessment is calculated by taking the average forecast from all of the analysts covering ABVC Biopharma.
Financial Strength
Based on the key measurements obtained from ABVC Biopharma's financial statements, ABVC Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of ABVC Biopharma is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00970.0102
Notably Down
Pretty Stable
Total Current Liabilities6.2 M5.9 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total407.7 K429.1 K
Notably Down
Very volatile
Total Assets15.7 M14.9 M
Sufficiently Up
Slightly volatile
Total Current Assets1.4 M1.7 M
Significantly Down
Slightly volatile
ABVC Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ABVC Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ABVC Biopharma's financial leverage. It provides some insight into what part of ABVC Biopharma's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on ABVC Biopharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how ABVC Biopharma deploys its capital and how much of that capital is borrowed.
Liquidity
ABVC Biopharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 0.34, which is about average as compared to similar companies. ABVC Biopharma has a current ratio of 2.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ABVC Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, ABVC Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ABVC Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ABVC to invest in growth at high rates of return. When we think about ABVC Biopharma's use of debt, we should always consider it together with cash and equity.

Change In Working Capital

1.03 Million
ABVC Biopharma (ABVC) is traded on NASDAQ Exchange in USA. It is located in 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538 and employs 16 people. ABVC Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ABVC Biopharma's market, we take the total number of its shares issued and multiply it by ABVC Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ABVC Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.56 M outstanding shares of which 637.62 K shares are presently shorted by private and institutional investors with about 0.41 trading days to cover. ABVC Biopharma currently holds about 2.99 M in cash with (4.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check ABVC Biopharma Probability Of Bankruptcy
Ownership Allocation
The market capitalization of ABVC Biopharma is $11.41 Million. ABVC Biopharma retains substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check ABVC Ownership Details

ABVC Stock Institutional Holders

Institutional Holdings refers to the ownership stake in ABVC Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ABVC Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ABVC Biopharma's value.
InstituionRecorded OnShares
Chase Investment Counsel Corp2024-03-31
178.4 K
Vanguard Group Inc2024-03-31
46.9 K
Renaissance Technologies Corp2023-12-31
36.1 K
Geode Capital Management, Llc2023-12-31
19.5 K
Tower Research Capital Llc2023-12-31
578
Spotlight Asset Group, Inc.2024-03-31
100.0
Royal Bank Of Canada2023-12-31
37.0
Wells Fargo & Co2023-12-31
20.0
Jpmorgan Chase & Co2023-12-31
0.0
Virtu Financial Llc2023-12-31
0.0
View ABVC Biopharma Diagnostics

ABVC Biopharma Historical Income Statement

ABVC Biopharma Income Statement is one of the three primary financial statements used for reporting ABVC's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ABVC Biopharma revenue and expense. ABVC Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, ABVC Biopharma's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 347.1 K, whereas Selling General Administrative is forecasted to decline to about 5 M. View More Fundamentals

ABVC Stock Against Markets

Picking the right benchmark for ABVC Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ABVC Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ABVC Biopharma is critical whether you are bullish or bearish towards ABVC Biopharma at a given time. Please also check how ABVC Biopharma's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in ABVC Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Analyzer Now

   

Portfolio Analyzer

Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
All  Next Launch Module

ABVC Biopharma Corporate Management

Elected by the shareholders, the ABVC Biopharma's board of directors comprises two types of representatives: ABVC Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABVC. The board's role is to monitor ABVC Biopharma's management team and ensure that shareholders' interests are well served. ABVC Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABVC Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
TsungShann JiangMember OfficerProfile
Leeds ChowChief OfficerProfile
Howard MDPres CEOProfile
ChiHsin KingChief OfficerProfile
Uttam PatilChief OfficerProfile
Eugene JiangChairman OfficerProfile

How to buy ABVC Stock?

Before investing in ABVC Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ABVC Biopharma. To buy ABVC Biopharma stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of ABVC Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase ABVC Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located ABVC Biopharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased ABVC Biopharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ABVC Biopharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ABVC Stock please use our How to Invest in ABVC Biopharma guide.

Already Invested in ABVC Biopharma?

The danger of trading ABVC Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ABVC Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ABVC Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ABVC Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for ABVC Stock analysis

When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is ABVC Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.43)
Revenue Per Share
0.035
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.43)
Return On Equity
(1.92)
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.